[CAR-T cell therapy in clinical practice]

Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable clinical efficacy in relapsed or refractory B-cell acute lymphoblastic leukemia, B-cell lymphoma, and multiple myeloma. In Japan, five CAR-T products have already been approved and have rapidly achieved widespread adoption in real-world clinical practice. CAR-T therapy involves multiple complex steps, including autologous T-cell collection, manufacturing, bridging therapy, infusion, and management of adverse events, each of which requires careful optimization. Disease relapse or progression after CAR-T therapy also remains common, which makes it crucial to accumulate clinical experience and evidence on post-treatment management. This review outlines the current clinical use of CAR-T cell therapy in Japan, discusses practical aspects of treatment delivery throughout the process, and examines its role relative to other emerging therapies.